



Supplementary figure 1. Flowchart to describe the selection to the current study.




*See Supplementary table 1 for baseline characteristics on low and intermediate risk non-muscle invasive bladder cancer in this group of patients.

Supplementary figure 2. Sensitivity analysis using recurrence or death related to bladder cancer as event for all 710 patients with primary intermediate risk (IR) non-muscle invasive bladder cancer stratified in low- and intermediate-IR (log-rank test $p=0.7$).



	Low-IR		Intermediate-IR			
At Risk	329	266	222	195	175	155
Events	0	55	95	113	119	129
	Low-IR		Intermediate-IR			
At Risk	381	280	232	206	187	165
Events	0	91	120	132	138	145


Supplementary figure 3. Recurrence-free survival (RFS) for the 152 patients with primary intermediate risk (IR) non-muscle invasive bladder cancer receiving adjuvant serial instillations stratified into low- and intermediate-IR (log-rank test $p=0.9$).



— Low-IR
 — Intermediate-IR

	Low-IR					
At Risk	72	58	53	48	43	39
Events	0	14	19	24	29	33
	Intermediate-IR					
At Risk	80	68	59	55	49	44
Events	0	12	21	25	31	36

Supplementary figure 4. Recurrence-free survival (RFS) for the 558 patients with primary intermediate risk (IR) non-muscle invasive bladder cancer not receiving adjuvant serial instillations stratified into low- and intermediate-IR (log-rank test $p=0.1$).



Low-IR Intermediate-IR

	0	1	2	3	4	5
Low-IR						
At Risk	257	208	169	147	132	116
Events	0	49	88	110	125	141
Intermediate-IR						
At Risk	301	212	173	151	138	121
Events	0	89	128	148	161	178